Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on NPJ Precision Oncology
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in NPJ Precision Oncology by Genentech, Inc.: Title: “Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology” This study reported that treatment of TGF-β neutralizing antibody in the…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Cellular and Molecular Gastroenterology and Hepatology
We announced that the results of the study in the STAM™ mouse model of NASH has been published in Cellular and Molecular Gastroenterology and Hepatology by Kawasaki Medical School: Title: “Dipeptidyl Peptidase 4 inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice” The authors demonstrated that Sitagliptin, a DPP-4 inhibitor, attenuated development of…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Glycoconjugate Journal
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Glycoconjugate Journal by Shionogi & Co., Ltd.: Title: “Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM mice” This study reports unique glycoisoforms as candidates…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Liver Cancer
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Liver Cancer by Kurume University: Title: “Effects of a DPP4 inhibitor on progression of NASH-related HCC and the p62/Keap1/Nrf2-Pentose phosphate pathway in a mouse model” The results of the study demonstrated in the…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on PLoS One
We announced that a study in the STAM mouse model of NASH performed by SMC Laboratories Inc. has been published in PLoS One by Gemphire Therapeutics: Title: “Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH” The results of the study demonstrated Gemcabene in the STAM™ model showed a reduction…
2025.02.02
One of our clients published preclinical data on the FASEB Journa
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model on The FASEB Journal. Title: “Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma” By using STAMTM model (NASH-HCC model), they demonstrated that advanced…
2025.02.02
One of our clients published preclinical data on NASH on Oncotarget
One of our clients Kanazawa University has published the results of a study using STAMTM model on Oncotarget. Title: “Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet” The data of STAMTM mice is available in the Supplemental Figure 2 from the following link (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522259/bin/oncotarget-08-39978-s001.pdf)…
2025.02.02
Our clients published preclinical data on NASH on Molecular Cancer Research
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model on Molecular Cancer Research. Title: “Inhibition of the cell death pathway in non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis is associated with histone H4 lysine 16 deacetylation“ The results of the study identified a reduction of global…
2025.02.02
Our clients published preclinical data on NASH-HCC on Oncotarget
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model on Oncotarget. Title: “MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis” By using STAMTM model (NASH-HCC model), they demonstrated that altered miRNA expression was associated with activation of major hepatocarcinogenesis-related pathway, including the TGF-b, Wnt/b-catenin,…
2025.02.02
Client Publication Announcement / European Radiology Experimental
We would like to introduce an update regarding a new article published by our client in European Radiology Experimental. Juntendo University Title: Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH) This paper examines whether the resistance (impedance) of free fatty acid (FFA) in the liver can be used…
We can help you advance your research.